ArticleActa bio-medica : Atenei Parmensis2021
Seroprevalence of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection in an Italian cohort in Marche Region, Italy.
Article in Acta bio-medica : Atenei Parmensis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Epidemiology of SARS-CoV-2 Infection in Italy Using Real-World Data: Methodology and Cohort Description of the Second Phase of Web-Based EPICOVID19 Study.International journal of environmental research and public health · 2022Trial
- Can smoking prevalence explain COVID-19 indicators (cases, mortality, and recovery)? A comparative study in OECD countries.Environmental science and pollution research international · 2022Article
- Article
- Article
- Seroprevalence of SARS-CoV-2 in a Large Cohort of Italian Police Officers.International journal of environmental research and public health · 2021Article
- SARS-CoV-2 IgG seropositivity in a cohort of 449 non-hospitalized individuals during Spanish COVID-19 lockdown.Scientific reports · 2021Observational
- Prevalence of SARS-CoV-2 infection in the workplace: results of a year of investigation in the Marche Nord companies.Acta bio-medica : Atenei Parmensis · 2021Article
- Impact of Two Different Recruitment Procedures (Random vs. Volunteer Selection) on the Results of Seroepidemiological Study (SARS-CoV-2).International journal of environmental research and public health · 2021Article
- Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak.Diagnostics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimThe COVID-19 is an infectious disease caused by the novel coronavirus SARS-CoV-2, declared a public health emergency by the World Health Organization. In this study, we evaluated the seroconversion of SARS-CoV-2 antibodies to find predictors of infection in terms of symptoms, health status, and professions.
methodsSerological samples of 341 volunteers in a cohort in Marche Region, Italy, were analyzed for the presence of IgM and/or IgG immunoglobulins specific for the SARS-CoV-2. Contextually, an anamnestic questionnaire was administered. The binary logistic regression analysis was used to find the predictors of seroconversion.
resultsForty-nine subjects (14.4 %) were found positive, without significant differences between gender and age groups. The predictors identified inside the variable categories "symptoms," "risk factors" (smoking habit and established pathologies), and "professions" were the loss of taste and smell (OR, 8.563), cardiovascular diseases (OR, 2.912), and policeman profession (OR, 3.875), respectively.
conclusionsAlthough the limited number of subjects recruited in this study, our results could give important findings to be considered for planning preventive strategies in the view of the next COVID-19 waves.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.